At a glance
ClinicalIndex Comparison RecordN/ACompleted· 641 enrolled
Drug / intervention
botulinum toxin Type Adrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 24-month, Prospective, Non-interventional Study to Describe the Long Term, Real-Life Use of BOTOX® for the Symptomatic Treatment of Adults With Chronic Migraine, Measuring Healthcare Resource Utilization, and Patient Reported Outcomes Observed in Practice
In Brief
An observational study evaluating botulinum toxin Type A for Migraine Disorders. Completed, enrolled 641 participants across 77 sites in 7 countries.
Detailed Summary
This is an observational study to describe the long term use of Onabotulinumtoxin A (BOTOX®) as prescribed by the physician for headache prophylaxis in adults with chronic migraine. All treatment decisions lie with the physician.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine Disorders
CountriesGermany, Italy, Norway, Russia, Spain, Sweden, United Kingdom
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2012
First PostedSep 2012
Primary CompletionOct 2016
TodayJul 2026
First PostedSep 18, 2012
Enrollment StartJul 23, 2012
Primary CompletionOct 12, 2016
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 13.8 years ago
Interventions
botulinum toxin Type Adrug
Botulinum toxin Type A (BOTOX®) administered according to physician prescription.